Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Volume 27, Number 3—March 2021

Synopsis

Decentralized Care for Rifampin-Resistant Tuberculosis, Western Cape, South Africa

Sarah V. LeavittComments to Author , Karen R. Jacobson, Elizabeth J. Ragan, Jacob Bor, Jennifer Hughes, Tara C. Bouton, Tania Dolby, Robin M. Warren, and Helen E. Jenkins
Author affiliations: Boston University, Boston, Massachusetts, USA (S.V. Leavitt, K.R. Jacobson, E.J. Ragan, J. Bor, T.C. Bouton, H.E. Jenkins); Boston Medical Center, Boston (K.R. Jacobson, E.J. Ragan, T.C. Bouton); University of the Witwatersrand, Johannesburg, South Africa (J. Bor); Stellenbosch University, Stellenbosch, South Africa (J. Hughes, R.M. Warren); Brown University, Providence, Rhode Island, USA (T.C. Bouton); Green Point Tuberculosis Laboratory, Cape Town, South Africa (T. Dolby); South African Medical Research Council Centre for Tuberculosis Research, Cape Town (R.M. Warren); Department of Science and Technology–National Research Foundation Centre of Excellence for Biomedical Tuberculosis Research, Cape Town (R.M. Warren)

Main Article

Table 2

Magnitude and duration of hospitalization and movement of patients with RR TB, Western Cape, South Africa, 2012–2014*

Description Overall, n = 2,878 Cape Town, n = 1,878 Outside Cape Town, n = 1,000 p value†
Hospitalization in TB hospital, no. (%) 
No. patients with >1 sample from a specialized TB hospital in the first year after RR TB diagnosis
 1,228 (42.7)
 545 (29.0)
 683 (68.3)
 <0.01
Moved to care outside TB hospital, no. (%)
No. patients with a sample from a TB hospital who had a subsequent sample from a non-TB hospital <3 mo after the most recent sample in the TB hospital
 837 (68.2)
 317 (58.2)
 520 (76.1)
 <0.01
Median length of TB hospital stay, d (IQR)
Median hospitalization period of patients who moved to care outside of a TB hospital in the first year after RR TB diagnosis
 99 (61–136)
 79 (50–118)
 108 (72–144)
 <0.01‡
Any movement, no. (%)
No. patients who had samples from >2 different facilities in first year after RR TB diagnosis
 1,765 (61.3)
 1,012 (53.9)
 753 (75.3)
 <0.01
Median no. of visits (IQR)
No. unique days with >1 laboratory sample in the first year after RR TB diagnosis
 9 (5–12)
 8 (4–12)
 10 (5–12)
 <0.01‡
Median total distance, km (IQR)
Total Euclidian distance between all facilities visited by each patient in the first year after RR TB diagnosis
 4.4 (0.0–41)
 1.5 (0.0–20)
 46.0 (0.2–122)
 <0.01‡
Median distance between consecutive visits, km (IQR)
Median distance between facilities visited consecutively by each patient in the first year after RR TB diagnosis 2.7 (0.0–19.8) 1.4 (0.0–12.2) 24.0 (0.2–64.8) <0.01‡

*Patients without second-line resistance who attended >2 clinic visits. RR, rifampin-resistant; TB, tuberculosis.
†χ2 p values of patients in Cape Town versus outside Cape Town.
‡p values determined by Wilcoxon rank-sum test.

Main Article

Page created: January 29, 2021
Page updated: February 21, 2021
Page reviewed: February 21, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external